The venture capital company Ysios Capital, member of CATALONIA.HEALTH, participates in the Series B financing round of 135 million dollars of its investee company Adcendo. In addition, it reaffirms its commitment to Adcendo, after leading the Series A round in 2021 for a total of 100 million euros, now joining a prominent international investment union.
This operation, one of the most important of the year in Europe, positions Adcendo as a leader in the development of innovative therapies and demonstrates the ability of the European ecosystem to attract large-scale financing rounds, comparable to those closed in the United States.
Joël Jean-Mairet, Managing Partner of Ysios Capital and head of investment values: "Adcendo is in a unique position to lead the next generation of ADC therapies in oncology. Having led your previous round and now collaborate closely in this new operation strengthens our full confidence in your team, your science and your strategic vision... This round shows that Europe can compete with the United States in cutting-edge biotechnology.”
Related news:
Ysios Capital invests in Neurona Therapeutics $120 million Series E round (12 February 2024)
Comments